{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T23:54:43Z","timestamp":1766102083387,"version":"3.48.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"NIHR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Randomized trials have failed to show a consistent benefit of revascularization in patients with ischaemic cardiomyopathy. This study aimed to investigate whether a participant\u2019s baseline risk introduces heterogeneity in the treatment effect of percutaneous coronary intervention (PCI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>The REVIVED-BCIS2 trial randomised 700 participants with ischaemic cardiomyopathy to PCI plus optimal medical therapy (OMT) vs. OMT alone, 263 (37.6%) of whom experienced the primary outcome (all-cause mortality or hospitalization due to heart failure) during a median follow-up of 41 months. Pre-randomization data were used to develop a prediction model for the primary outcome, and evidence for heterogeneity of the trial intervention effect was investigated. The prediction model included 12 predictors and showed acceptable discrimination (C statistic: 0.69, 95% CI 0.66\u20130.72) and calibration (calibration slope: 0.79, 95% CI 0.64\u20130.95). Overall, there was no statistical evidence that the baseline risk score modified the trial intervention effect (pinteraction = 0.21) on the primary outcome. For the secondary outcome of cardiovascular death or hospitalization due to heart failure, weak evidence emerged that the baseline risk modified the trial intervention effect (pinteraction = 0.044). Participants with lower baseline risk trended towards a greater benefit from PCI compared with participants with higher risk scores.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Baseline risk did not influence the effect of revascularization in preventing all-cause mortality or hospitalization due to heart failure. A trend was observed that lower baseline risk might be associated with more benefit of revascularization in preventing cardiovascular death or hospitalization due to heart failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinicaltrials.gov identifier<\/jats:title>\n                    <jats:p>NCT01920048<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjqcco\/qcaf108","type":"journal-article","created":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T11:37:32Z","timestamp":1757849852000},"page":"1440-1447","source":"Crossref","is-referenced-by-count":0,"title":["Impact of baseline risk of death or hospitalization on effectiveness of revascularization in patients with ischaemic left ventricular dysfunction\u2014a prespecified analysis of REVIVED-BCIS2"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4870-4475","authenticated-orcid":false,"given":"Christian","family":"Ovesen","sequence":"first","affiliation":[{"name":"Department of Medical Statistics, London School of Hygiene and Tropical Medicine , Keppel Street, London WC1E 7HT ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6207-6604","authenticated-orcid":false,"given":"Matthew","family":"Dodd","sequence":"additional","affiliation":[{"name":"Department of Medical Statistics, London School of Hygiene and Tropical Medicine , Keppel Street, London WC1E 7HT ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Ryan","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Medicine and Sciences, British Heart Foundation Centre of Research Excellence, King\u2019s College London, St Thomas\u2019 Hospital , Westminster Bridge Road, London SE1 7EH, UK"},{"name":"Cardiovascular Division, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust , Westminster Bridge Road, London SE1 7EH, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1266-3288","authenticated-orcid":false,"given":"Tim","family":"Clayton","sequence":"additional","affiliation":[{"name":"Department of Medical Statistics, London School of Hygiene and Tropical Medicine , Keppel Street, London WC1E 7HT ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Sharples","sequence":"additional","affiliation":[{"name":"Department of Medical Statistics, London School of Hygiene and Tropical Medicine , Keppel Street, London WC1E 7HT ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6362-1291","authenticated-orcid":false,"given":"Divaka","family":"Perera","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Medicine and Sciences, British Heart Foundation Centre of Research Excellence, King\u2019s College London, St Thomas\u2019 Hospital , Westminster Bridge Road, London SE1 7EH, UK"},{"name":"Cardiovascular Division, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust , Westminster Bridge Road, London SE1 7EH, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"key":"2025121818523402700_qcaf108-B1","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","author":"GBD Diseases and Injuries Collaborators","year":"2020","journal-title":"Lancet"},{"key":"2025121818523402700_qcaf108-B2","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/j.jacc.2022.11.005","article-title":"The global burden of cardiovascular diseases and risk: a compass for future health","volume":"80","author":"Vaduganathan","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2025121818523402700_qcaf108-B3","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2025121818523402700_qcaf108-B4","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"2025121818523402700_qcaf108-B5","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMoa1602001","article-title":"Coronary-artery bypass surgery in patients with ischemic cardiomyopathy","volume":"374","author":"Velazquez","year":"2016","journal-title":"N Engl J Med"},{"key":"2025121818523402700_qcaf108-B6","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1056\/NEJMoa1100356","article-title":"Coronary-artery bypass surgery in patients with left ventricular dysfunction","volume":"364","author":"Velazquez","year":"2011","journal-title":"N Engl J Med"},{"key":"2025121818523402700_qcaf108-B7","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1056\/NEJMoa2206606","article-title":"Percutaneous revascularization for ischemic left ventricular dysfunction","volume":"387","author":"Perera","year":"2022","journal-title":"N Engl J Med"},{"key":"2025121818523402700_qcaf108-B8","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jchf.2018.01.024","article-title":"Percutaneous revascularization for ischemic ventricular dysfunction: rationale and design of the REVIVED-BCIS2 trial: percutaneous coronary intervention for ischemic cardiomyopathy","volume":"6","author":"Perera","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2025121818523402700_qcaf108-B9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.7326\/M14-0697","article-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement","volume":"162","author":"Collins","year":"2015","journal-title":"Ann Intern Med"},{"key":"2025121818523402700_qcaf108-B10","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1161\/01.CIR.88.1.107","article-title":"Survival after the onset of congestive heart failure in Framingham Heart Study subjects","volume":"88","author":"Ho","year":"1993","journal-title":"Circulation"},{"key":"2025121818523402700_qcaf108-B11","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1001\/archinte.162.15.1689","article-title":"Prognosis and determinants of survival in patients newly hospitalized for heart failure: a population-based study","volume":"162","author":"Jong","year":"2002","journal-title":"Arch Intern Med"},{"key":"2025121818523402700_qcaf108-B12","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/j.jacc.2003.12.053","article-title":"Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data","volume":"43","author":"Wong","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"2025121818523402700_qcaf108-B13","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1161\/CIRCULATIONAHA.116.024800","article-title":"Ten-year outcomes after coronary artery bypass grafting according to age in patients with heart failure and left ventricular systolic dysfunction: an analysis of the extended follow-up of the STICH trial (surgical treatment for ischemic heart failure)","volume":"134","author":"Petrie","year":"2016","journal-title":"Circulation"},{"key":"2025121818523402700_qcaf108-B14","doi-asserted-by":"crossref","first-page":"E683","DOI":"10.25270\/jic\/21.00435","article-title":"Coronary jeopardy score predicts ischemic etiology in patients with left ventricular systolic dysfunction","volume":"34","author":"Morgan","year":"2022","journal-title":"J Invasive Cardiol"},{"key":"2025121818523402700_qcaf108-B15","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0140-6736(13)60108-7","article-title":"Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II","volume":"381","author":"Farooq","year":"2013","journal-title":"Lancet"},{"key":"2025121818523402700_qcaf108-B16","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jclinepi.2003.08.009","article-title":"Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test","volume":"57","author":"Brookes","year":"2004","journal-title":"J Clin Epidemiol"},{"key":"2025121818523402700_qcaf108-B17","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1742-5573-4-4","article-title":"Power for tests of interaction: effect of raising the Type I error rate","volume":"4","author":"Marshall","year":"2007","journal-title":"Epidemiol Perspect Innov"},{"key":"2025121818523402700_qcaf108-B18","doi-asserted-by":"crossref","first-page":"l2154","DOI":"10.1136\/bmj.l2154","article-title":"When and how to use data from randomised trials to develop or validate prognostic models","volume":"365","author":"Pajouheshnia","year":"2019","journal-title":"BMJ"},{"key":"2025121818523402700_qcaf108-B19","doi-asserted-by":"crossref","first-page":"e005531","DOI":"10.1161\/CIRCHEARTFAILURE.118.005531","article-title":"Society of thoracic surgeons risk score and EuroSCORE-2 appropriately assess 30-day postoperative mortality in the STICH trial and a contemporary cohort of patients with left ventricular dysfunction undergoing surgical revascularization","volume":"11","author":"Bouabdallaoui","year":"2018","journal-title":"Circ Heart Fail"},{"key":"2025121818523402700_qcaf108-B20","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jchf.2014.02.009","article-title":"Exercise capacity and mortality in patients with ischemic left ventricular dysfunction randomized to coronary artery bypass graft surgery or medical therapy: an analysis from the STICH trial (surgical treatment for ischemic heart failure)","volume":"2","author":"Stewart","year":"2014","journal-title":"JACC Heart Fail"},{"key":"2025121818523402700_qcaf108-B21","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1093\/eurheartj\/ehaf080","article-title":"Medical therapy and outcomes in REVIVED-BCIS2 and STICHES: an individual patient data analysis","volume":"46","author":"Ryan","year":"2025","journal-title":"Eur Heart J"},{"key":"2025121818523402700_qcaf108-B22","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1093\/eurheartj\/ehab703","article-title":"Five-year outcomes after state-of-the-art percutaneous coronary revascularization in patients with de novo three-vessel disease: final results of the SYNTAX II study","volume":"43","author":"Banning","year":"2022","journal-title":"Eur Heart J"},{"key":"2025121818523402700_qcaf108-B23","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1161\/CIRCULATIONAHA.120.050304","article-title":"Initial invasive versus conservative management of stable ischemic heart disease in patients with a history of heart failure or left ventricular dysfunction: insights from the ISCHEMIA trial","volume":"142","author":"Lopes","year":"2020","journal-title":"Circulation"},{"key":"2025121818523402700_qcaf108-B24","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0735-1097(02)01726-6","article-title":"Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis","volume":"39","author":"Allman","year":"2002","journal-title":"J Am Coll Cardiol"}],"container-title":["European Heart Journal - Quality of Care and Clinical Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjqcco\/advance-article-pdf\/doi\/10.1093\/ehjqcco\/qcaf108\/64288486\/qcaf108.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article-pdf\/11\/8\/1440\/64288486\/qcaf108.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article-pdf\/11\/8\/1440\/64288486\/qcaf108.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T23:52:49Z","timestamp":1766101969000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article\/11\/8\/1440\/8256345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,16]]},"references-count":24,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,9,16]]},"published-print":{"date-parts":[[2025,12,19]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjqcco\/qcaf108","relation":{},"ISSN":["2058-5225","2058-1742"],"issn-type":[{"type":"print","value":"2058-5225"},{"type":"electronic","value":"2058-1742"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,9,16]]}}}